{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:04:59Z","timestamp":1793387099271,"version":"4.5.0"},"reference-count":117,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,8,21]],"date-time":"2013-08-21T00:00:00Z","timestamp":1377043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,8,21]],"date-time":"2013-08-21T00:00:00Z","timestamp":1377043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Med. Toxicol."],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s13181-013-0325-8","type":"journal-article","created":{"date-parts":[[2013,8,20]],"date-time":"2013-08-20T16:47:59Z","timestamp":1377017279000},"page":"26-39","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":302,"title":["A Review of the Toxicity of HIV Medications"],"prefix":"10.1007","volume":"10","author":[{"given":"Asa M.","family":"Margolis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Heverling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Stolbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,21]]},"reference":[{"issue":"4","key":"325_CR1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/jama.2012.7961","volume":"308","author":"MA Thompson","year":"2012","unstructured":"Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P et al (2012) Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 308(4):387","journal-title":"JAMA"},{"issue":"24","key":"325_CR2","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1056\/NEJMoa030265","volume":"349","author":"RW Shafer","year":"2003","unstructured":"Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, D\u2019Aquila RT, Johnson VA, Morse GD, Nokta MA, Martinez AI, Gripshover BM, Kaul P, Haubrich R, Swingle M, McCarty SD, Vella S, Hirsch MS, Merigan TC, AIDS Clinical Trials Group 384 Team (2003) Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 349(24):2304","journal-title":"N Engl J Med"},{"issue":"4","key":"325_CR3","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1086\/596482","volume":"48","author":"JJ Parienti","year":"2009","unstructured":"Parienti JJ, Bangsberg DR, Verdon R, Gardner EM (2009) Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis 48(4):484\u2013488","journal-title":"Clin Infect Dis"},{"issue":"2","key":"325_CR4","first-page":"129","volume":"48","author":"F Maignen","year":"1993","unstructured":"Maignen F, Meglio S, Bidault I, Castot A (1993) Acute toxicity of zidovudine. Analysis of the literature and number of cases at the Paris Poison Control Center. Therapie 48(2):129\u201331","journal-title":"Therapie"},{"issue":"8","key":"325_CR5","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3109\/15563650.2011.602081","volume":"49","author":"Z Livshits","year":"2011","unstructured":"Livshits Z, Lee S, Hoffman RS, Nelson LS, Esteban-Cruciani N (2011) Zidovudine (AZT) overdose in a healthy newborn receiving postnatal prophylaxis. Clin Toxicol (Phila) 49(8):747\u20139, Epub 2011 Aug 25","journal-title":"Clin Toxicol (Phila)"},{"issue":"2","key":"325_CR6","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/QAD.0b013e3282f33580","volume":"22","author":"E Chiappini","year":"2008","unstructured":"Chiappini E, Galli L, Gabiano C, Gattinara GC, Martino A, Scolfaro C et al (2008) Preventable zidovudine overdose during postnatal prophylaxis in healthy children born to HIV-1-positive mothers. AIDS 22(2):316\u20137","journal-title":"AIDS"},{"issue":"6","key":"325_CR7","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00431-007-0541-9","volume":"167","author":"JF Brasme","year":"2008","unstructured":"Brasme JF, Mille F, Benhayoun M, Bavoux F, Faye A, Teissier N et al (2008) Uncomplicated outcome after an accidental overdose of nevirapine in a newborn. Eur J Pediatr 167(6):689\u201390, Epub 2007 Jun 29","journal-title":"Eur J Pediatr"},{"key":"325_CR8","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3109\/15563650.2012.746424","volume":"50","author":"AC Bronstein","year":"2012","unstructured":"Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Dart RC (2012) 2011 Annual Report of the American Association of Poison Control Centers\u2019 National Poison Data System (NPDS): 29th Annual Report. Clin Toxicol (Phila) 50:911\u20131164","journal-title":"Clin Toxicol (Phila)"},{"key":"325_CR9","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3109\/15563650.2011.635149","volume":"49","author":"AC Bronstein","year":"2011","unstructured":"Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Dart RC (2011) 2010 Annual Report of the American Association of Poison Control Centers\u2019 National Poison Data System (NPDS): 28th Annual Report. Clin Toxicol (Phila) 49:910\u2013941","journal-title":"Clin Toxicol (Phila)"},{"issue":"10","key":"325_CR10","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3109\/15563650.2010.543906","volume":"48","author":"AC Bronstein","year":"2010","unstructured":"Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Giffin SL (2010) 2009 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 27th Annual Report. Clin Toxicol (Phila) 48(10):979\u20131178","journal-title":"Clin Toxicol (Phila)"},{"issue":"10","key":"325_CR11","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3109\/15563650903438566","volume":"47","author":"AC Bronstein","year":"2009","unstructured":"Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Giffin SL (2009) 2008 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th Annual Report. Clin Toxicol (Phila) 47(10):911\u20131084","journal-title":"Clin Toxicol (Phila)"},{"issue":"10","key":"325_CR12","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/15563650802559632","volume":"46","author":"AC Bronstein","year":"2008","unstructured":"Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Heard SE (2008) 2007 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 25th Annual Report. Clin Toxicol (Phila) 46(10):927\u20131057","journal-title":"Clin Toxicol (Phila)"},{"issue":"5","key":"325_CR13","first-page":"353","volume":"21","author":"WA William","year":"2002","unstructured":"William WA, Litovitz TL, Rodgers GC, Klein-Schwartz W, Youniss J, Rose SR, Borys D, May ME (2002) Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System (2003). Am J Emergency Med 21(5):353\u2013421","journal-title":"Am J Emergency Med"},{"issue":"2","key":"325_CR14","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2165\/00003495-200060020-00015","volume":"60","author":"PS Hervey","year":"2000","unstructured":"Hervey PS, Perry CM (2000) Abacavir: a review of its clinical potential in patients with HIV infection. Drugs 60(2):447\u2013479","journal-title":"Drugs"},{"issue":"9308","key":"325_CR15","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","volume":"359","author":"S Mallal","year":"2002","unstructured":"Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C et al (2002) Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359(9308):727\u2013732","journal-title":"Lancet"},{"issue":"10","key":"325_CR16","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0149-2918(02)80057-1","volume":"24","author":"PG Clay","year":"2002","unstructured":"Clay PG (2002) The abacavir hypersensitivity reaction: a review. Clin Ther 24(10):1502\u20131514","journal-title":"Clin Ther"},{"issue":"9622","key":"325_CR17","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","volume":"371","author":"CA Sabin","year":"2008","unstructured":"D:A:D Study Group, Sabin CA, Worm SW, Weber R et al (2008) Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 371(9622):1417","journal-title":"Lancet"},{"issue":"16","key":"325_CR18","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1097\/QAD.0b013e328349c6ee","volume":"25","author":"M Cruciani","year":"2011","unstructured":"Cruciani M, Zanichelli V, Serpelloni G, Bosco O, Malena M, Mazzi R et al (2011) Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS 25(16):1993\u20132004","journal-title":"AIDS"},{"issue":"10","key":"325_CR19","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.2165\/00003495-200767100-00006","volume":"67","author":"S Moreno","year":"2007","unstructured":"Moreno S, Hern\u00e1ndez B, Dronda F (2007) Didanosine enteric-coated capsule: current role in patients with HIV-1 infection. Drugs 67(10):1441\u20131462","journal-title":"Drugs"},{"issue":"2","key":"325_CR20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/infdis\/175.2.255","volume":"175","author":"M Floridia","year":"1997","unstructured":"Floridia M, Vella S, Seeber AC, Tomino C, Fragola V, Weimer LE et al (1997) A randomized trial (ISS 902) of didanosine versus zidovudine in previously untreated patients with mildly symptomatic human immunodeficiency virus infection. J Infect Dis 175(2):255\u2013264","journal-title":"J Infect Dis"},{"issue":"1","key":"325_CR21","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1086\/498348","volume":"42","author":"MS Saag","year":"2006","unstructured":"Saag MS (2006) Emtricitabine. a new antiretroviral agent with activity against HIV and hepatitis B virus. Clin Infect Dis 42(1):126\u2013131, Epub 2005. Nov 23","journal-title":"Clin Infect Dis"},{"key":"325_CR22","unstructured":"Drugs @ FDA [webpage on the Internet]. FDA approved drug products. Silver Spring, MD: U.S. Food and Drug Administration [updated 2012 July 23; cited 2012 Dec 1]. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021500s019lbl.pdf)"},{"issue":"16","key":"325_CR23","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1097\/00002030-199911120-00006","volume":"13","author":"KH Moore","year":"1999","unstructured":"Moore KH, Barrett JE, Shaw S, Pakes GE, Churchus R, Kapoor A et al (1999) The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS 13(16):2239\u20132250","journal-title":"AIDS"},{"issue":"1","key":"325_CR24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1365-2125.1998.00044.x","volume":"46","author":"MA Johnson","year":"1998","unstructured":"Johnson MA, Verpooten GA, Daniel MJ, Plumb R, Moss J, Van Caesbroeck D et al (1998) Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis. Br J Clin Pharmacol 46(1):21\u201327","journal-title":"Br J Clin Pharmacol"},{"key":"#cr-split#-325_CR25.1","unstructured":"Drugs @ FDA [webpage on the Internet]. FDA approved drug products. Silver Spring, MD: U.S. Food and Drug Administration. [updated 2011 Nov 18"},{"key":"#cr-split#-325_CR25.2","unstructured":"cited 2012 Dec 1]. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020564s031,020596s030lbl.pdf"},{"issue":"5","key":"325_CR26","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2165\/00003495-199958050-00012","volume":"58","author":"M Hurst","year":"1999","unstructured":"Hurst M, Noble S (1999) Stavudine: an update of its use in the treatment of HIV infection. Drugs 58(5):919\u2013949","journal-title":"Drugs"},{"issue":"15","key":"325_CR27","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2165\/00003495-200363150-00006","volume":"63","author":"T Chapman","year":"2003","unstructured":"Chapman T, McGavin J, Noble S (2003) Tenofovir disoproxil fumarate. Drugs 63(15):1597\u20131608","journal-title":"Drugs"},{"issue":"5","key":"325_CR28","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/QAD.0b013e32834f337c","volume":"26","author":"J Young","year":"2012","unstructured":"Young J, Scha\u00a8 fer J, Fux CA, Furrer H, Bernasconni E, Vernazza P, Calmy A, Cavassani M, Weber R, Battegay M, Bucher HC, Swiss HIV Cohort Study (2012) Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. AIDS 26(5):567\u2013575","journal-title":"AIDS"},{"issue":"11","key":"325_CR29","doi-asserted-by":"crossref","first-page":"C3","DOI":"10.1111\/j.1525-1497.2006.00518.x","volume":"21","author":"G Mathew","year":"2006","unstructured":"Mathew G, Knaus SJ (2006) Acquired Fanconi's syndrome associated with tenofovir therapy. J Gen Intern Med 21(11):C3\u2013C5","journal-title":"J Gen Intern Med"},{"issue":"7","key":"325_CR30","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/QAD.0b013e328351f68f","volume":"26","author":"R Scherzer","year":"2012","unstructured":"Scherzer R, Estrella M, Li Y, Choi AI, Deeks SG, Grunfeld C et al (2012) Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 26(7):867\u2013875","journal-title":"AIDS"},{"key":"325_CR31","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1093\/infdis\/171.Supplement_2.S99","volume":"171","author":"MN Dudley","year":"1995","unstructured":"Dudley MN (1995) Clinical pharmacokinetics of nucleoside antiretroviral agents. J Infect Dis 171:S99\u2013112","journal-title":"J Infect Dis"},{"issue":"7","key":"325_CR32","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJM199508173330702","volume":"333","author":"S Kinloch-De Loes","year":"1995","unstructured":"Kinloch-De Loes S, Hirschel BJ, Hoen B, Cooper DA, Tindall B, Carr A et al (1995) A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 333(7):408\u2013413","journal-title":"N Engl J Med"},{"issue":"6","key":"325_CR33","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0149-2918(00)90004-3","volume":"22","author":"TN Kakuda","year":"2000","unstructured":"Kakuda TN (2000) Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 22(6):685\u2013708","journal-title":"Clin Ther"},{"issue":"10","key":"325_CR34","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/nrd1201","volume":"2","author":"W Lewis","year":"2003","unstructured":"Lewis W, Day BJ, Copeland WC (2003) Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2(10):812\u2013822","journal-title":"Nat Rev Drug Discov"},{"issue":"14","key":"325_CR35","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1097\/00002030-199814000-00004","volume":"12","author":"K Brinkman","year":"1998","unstructured":"Brinkman K, ter Hofstede HJM, Burger DM, Smeitink JA, Koopmans PP (1998) Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as a common pathway. AIDS 12(14):1735\u20131744","journal-title":"AIDS"},{"issue":"2","key":"325_CR36","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00002030-200401230-00002","volume":"18","author":"A Cossarizza","year":"2004","unstructured":"Cossarizza A, Moyle G (2004) Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS 18(2):137\u2013151","journal-title":"AIDS"},{"issue":"1","key":"325_CR37","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1006\/taap.2001.9288","volume":"177","author":"SD Sales","year":"2001","unstructured":"Sales SD, Hoggard PG, Sunderland D, Khoo S, Hart CA, Back DJ (2001) Zidovudine phosphorylation and mitochondrial toxicity in vitro. Toxicol Appl Pharmacol 177(1):54\u201358","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"325_CR38","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000134943","volume":"82","author":"ER Scruggs","year":"2008","unstructured":"Scruggs ER, Dirks Naylor AJ (2008) Mechanisms of zidovudine-induced mitochondrial toxicity and myopathy. Pharmacology 82(2):83\u201388, Epub 2008May 27","journal-title":"Pharmacology"},{"issue":"8","key":"325_CR39","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0149-2918(00)80064-8","volume":"22","author":"G Moyle","year":"2000","unstructured":"Moyle G (2000) Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 22(8):911\u2013936, discussion 898","journal-title":"Clin Ther"},{"issue":"8740","key":"325_CR40","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/0140-6736(91)91294-5","volume":"337","author":"E Arnaudo","year":"1991","unstructured":"Arnaudo E, Dalakas M, Shanske S, Moraes CT, DiMauro S, Schon EA (1991) Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 337(8740):508\u2013510","journal-title":"Lancet"},{"issue":"16","key":"325_CR41","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJM199004193221602","volume":"322","author":"MC Dalakas","year":"1990","unstructured":"Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL (1990) Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 322(16):1098\u20131105","journal-title":"N Engl J Med"},{"issue":"4","key":"325_CR42","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/ana.410350418","volume":"35","author":"MC Dalakas","year":"1994","unstructured":"Dalakas MC, Leon-Monzon ME, Bernardini I, Gahl WA, Jay CA (1994) Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage. Ann Neurol 35(4):482\u2013487","journal-title":"Ann Neurol"},{"issue":"1","key":"325_CR43","first-page":"5","volume":"86","author":"BS Peters","year":"1993","unstructured":"Peters BS, Winer J, Landon DN, Stotter A, Pinching AJ (1993) Mitochondrial myopathy associated with chronic zidovudine therapy in AIDS. Q J Med 86(1):5\u201315","journal-title":"Q J Med"},{"issue":"2","key":"325_CR44","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/01.qai.0000182230.47819.aa","volume":"40","author":"P Bacchetti","year":"2005","unstructured":"Bacchetti P, Gripshover B, Grunfeld C, Heymsfield S, McCreath H, Osmond D, Saag M, Scherzer R, Shlipak M, Tien P, Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM) (2005) Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 40(2):121\u2013131","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"14","key":"325_CR45","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1097\/00002030-200109280-00009","volume":"15","author":"CM Shikuma","year":"2001","unstructured":"Shikuma CM, Hu N, Milne C, Yost F, Waslien C, Shimizu S et al (2001) Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 15(14):1801\u20131809","journal-title":"AIDS"},{"issue":"2","key":"325_CR46","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1086\/380790","volume":"38","author":"GA McComsey","year":"2004","unstructured":"McComsey GA, Ward DJ, Hessenthaler SM, Sension MG, Shalit P, Lonergan JT, Fisher RL, Williams VC, Hernandez JE, Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL, ESS40010) Study Team (2004) Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 38(2):263\u2013270, Epub 2003 Dec 18","journal-title":"Clin Infect Dis"},{"issue":"10","key":"325_CR47","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1212\/WNL.44.10.1892","volume":"44","author":"H Bacellar","year":"1994","unstructured":"Bacellar H, Munoz A, Miller EN, Cohen BA, Besley D, Selnes OA et al (1994) Temporal trends in the incidence of HIV-1-related neurologic diseases: multicenter AIDS Cohort Study, 1985\u20131992. Neurology 44(10):1892\u20131900","journal-title":"Neurology"},{"issue":"9","key":"325_CR48","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1474-4422(05)70165-4","volume":"4","author":"JC McArthur","year":"2005","unstructured":"McArthur JC, Brew BJ, Nath A (2005) Neurological complications of HIV infection. Lancet Neurol 4(9):543\u2013555","journal-title":"Lancet Neurol"},{"issue":"6","key":"325_CR49","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2165\/00003495-200059060-00005","volume":"59","author":"EA Wulff","year":"2000","unstructured":"Wulff EA, Wang AK, Simpson DM (2000) HIV-associated peripheral neuropathy: epidemiology, pathophysiology and treatment. Drugs 59(6):1251\u20131260","journal-title":"Drugs"},{"issue":"5","key":"325_CR50","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1212\/WNL.38.5.794","volume":"38","author":"DR Cornblath","year":"1988","unstructured":"Cornblath DR, McArthur JC (1988) Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex. Neurology 38(5):794\u2013796","journal-title":"Neurology"},{"issue":"11","key":"325_CR51","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1212\/01.wnl.0000218303.48113.5d","volume":"66","author":"Simpson DM, Kitch D, Evans SR, McArthur JC, Asmuth DM, Cohen B, Goodkin K, Gerschenson M, So Y, Marra CM, Diaz-Arrastia R, Shriver S, Millar L, Clifford DB, ACTG A547 Study Group","year":"2006","unstructured":"Simpson DM, Kitch D, Evans SR, McArthur JC, Asmuth DM, Cohen B, Goodkin K, Gerschenson M, So Y, Marra CM, Diaz-Arrastia R, Shriver S, Millar L, Clifford DB, ACTG A547 Study Group (2006) HIV neuropathy natural history cohort study: assessment measures and risk factors. Neurology 66(11):1679\u20131687","journal-title":"Neurology"},{"issue":"1","key":"325_CR52","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/infdis\/167.1.21","volume":"167","author":"MJ Browne","year":"1993","unstructured":"Browne MJ, Mayer KH, Chafee SB, Dudley MN, Posner MR, Steinberg SM et al (1993) 2\u2019, 3\u2019-Didehydro-3\u2019-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J Infect Dis 167(1):21\u201329","journal-title":"J Infect Dis"},{"issue":"2","key":"325_CR53","first-page":"153","volume":"9","author":"DM Simpson","year":"1995","unstructured":"Simpson DM, Tagliati M (1995) Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J Acquir Immune defic Syndr Hum Retrovirol 9(2):153\u2013161","journal-title":"J Acquir Immune defic Syndr Hum Retrovirol"},{"issue":"3","key":"325_CR54","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00126334-200207010-00002","volume":"30","author":"CL Cherry","year":"2002","unstructured":"Cherry CL, Gahan ME, McArthur J, Lewin SR, Hoy JF, Wesseling SL (2002) Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. J Acquir Immune Defic Syndr 30(3):271\u2013277","journal-title":"J Acquir Immune Defic Syndr"},{"key":"325_CR55","first-page":"306","volume":"38","author":"JW Russel","year":"1995","unstructured":"Russel JW, Cupler EJ, Dalakas MC (1995) Electrophysiological and pathological changes in 2\u2019,3\u2019-dideoxycytidine (ddC)-induced myopathy in an animal model. Ann Neurol 38:306","journal-title":"Ann Neurol"},{"issue":"1","key":"325_CR56","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1046\/j.1529-8027.2001.006001014.x","volume":"6","author":"MC Dalakas","year":"2001","unstructured":"Dalakas MC (2001) Peripheral neuropathy and antiretroviral drugs. J Peripher Nerv Syst 6(1):14\u201320","journal-title":"J Peripher Nerv Syst"},{"issue":"11","key":"325_CR57","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1086\/323783","volume":"33","author":"ME Coghlan","year":"2001","unstructured":"Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA (2001) Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clin Infect Dis 33(11):1914\u20131921, Epub 2001Oct 24","journal-title":"Clin Infect Dis"},{"issue":"3","key":"325_CR58","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1046\/j.1432-1033.2003.03947.x","volume":"271","author":"K Bartlett","year":"2004","unstructured":"Bartlett K, Eaton S (2004) Mitochondrial beta-oxidation. Eur J Biochem 271(3):462\u2013469","journal-title":"Eur J Biochem"},{"issue":"4","key":"325_CR59","doi-asserted-by":"crossref","first-page":"283","DOI":"10.7326\/0003-4819-115-4-283","volume":"115","author":"KK Lai","year":"1991","unstructured":"Lai KK, Gang DL, Zawacki JK, Cooley TP (1991) Fulminant hepatic failure associated with 2',3'-dideoxyinosine (ddI). Ann Intern Med 115(4):283\u2013284","journal-title":"Ann Intern Med"},{"issue":"1","key":"325_CR60","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.clnu.2004.03.009","volume":"24","author":"L Calza","year":"2005","unstructured":"Calza L, Manfredi R, Chiodo F (2005) Hyperlactatemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy. Clin Nutr 24(1):5\u201315","journal-title":"Clin Nutr"},{"issue":"1","key":"325_CR61","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1086\/313912","volume":"31","author":"JT Lonergan","year":"2000","unstructured":"Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC (2000) Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 31(1):162\u2013166, Epub 2000 Jul 26","journal-title":"Clin Infect Dis"},{"issue":"6","key":"325_CR62","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/00002030-200104130-00007","volume":"15","author":"M John","year":"2001","unstructured":"John M, Moore CB, James IR, Nolan D, Upton RP, McKinnon EJ et al (2001) Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 15(6):717\u2013723","journal-title":"AIDS"},{"issue":"6","key":"325_CR63","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1086\/339041","volume":"34","author":"V Falc\u00f3","year":"2002","unstructured":"Falc\u00f3 V, Rodr\u00edguez D, Ribera E, Mart\u00ednez E, Mir\u00f3 JM, Domingo P, Diazaraque R et al (2002) Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis 34(6):838\u2013846, Epub 2002, Feb 13","journal-title":"Clin Infect Dis"},{"issue":"18","key":"325_CR64","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1097\/QAD.0b013e3282f08cdc","volume":"21","author":"Lactic Acidosis International Study Group","year":"2007","unstructured":"Lactic Acidosis International Study Group (2007) Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. AIDS 21(18):2455\u20132464","journal-title":"AIDS"},{"issue":"5","key":"325_CR65","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1086\/423176","volume":"39","author":"O Miro","year":"2004","unstructured":"Miro O, Lopez S, Martinez E, Pedrol E, Milinkovic A, Deig E et al (2004) Mitochondrial effects of HIV infection on the peripheral blood mononuclear cells of HIV-infected patients who were never treated with antiretrovirals. Clin Infect Dis 39(5):710\u2013716, Epub 2004, Aug 13","journal-title":"Clin Infect Dis"},{"issue":"3","key":"325_CR66","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1128\/AAC.46.3.716-723.2002","volume":"46","author":"G Birkus","year":"2002","unstructured":"Birkus G, Hitchcock MJ, Cihlar T (2002) Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 46(3):716\u2013723","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"325_CR67","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/00002030-200104130-00016","volume":"15","author":"K Brinkman","year":"2001","unstructured":"Brinkman K (2001) Management of hyperlactatemia: no need for routine lactate measurements. AIDS 15(6):795\u2013797","journal-title":"AIDS"},{"issue":"9124","key":"325_CR68","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(05)60266-8","volume":"352","author":"B Fouty","year":"1998","unstructured":"Fouty B, Frerman F, Reves R (1998) Riboflavin to treat nucleoside analogue-induced lactic acidosis. Lancet 352(9124):291\u2013292","journal-title":"Lancet"},{"issue":"4","key":"325_CR69","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/00002030-200003100-00029","volume":"14","author":"YE Claessens","year":"2000","unstructured":"Claessens YE, Cariou A, Chiche JD, Dauriat G, Dhainaut JF (2000) l-Carnitine as a treatment of life-threatening lactic acidosis induced by nucleoside analogues. AIDS 14(4):472\u2013473","journal-title":"AIDS"},{"issue":"5","key":"325_CR70","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/00002030-200203290-00021","volume":"16","author":"N Venhoff","year":"2002","unstructured":"Venhoff N, Setzer B, Lebrecht D, Walker UA (2002) Dietary supplements in the treatment of nucleoside reverse transcriptase inhibitor-related mitochondrial toxicity. AIDS 16(5):800\u2013802","journal-title":"AIDS"},{"issue":"11","key":"325_CR71","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa012035","volume":"346","author":"HC C\u00f4t\u00e9","year":"2002","unstructured":"C\u00f4t\u00e9 HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L et al (2002) Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 346(11):811\u2013820","journal-title":"N Engl J Med"},{"issue":"5","key":"325_CR72","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/infdis\/172.5.1379","volume":"172","author":"D Havlir","year":"1995","unstructured":"Havlir D, McLaughlin MM, Richman DD (1995) A pilot study to evaluate the development of resistance to nevirapine in asymptomatic human immunodeficiency virus-infected patients with CD4 cell counts of >500\/mm3: AIDS Clinical Trials Group Protocol 208. J Infect Dis 172(5):1379\u20131383","journal-title":"J Infect Dis"},{"issue":"3","key":"325_CR73","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1310\/4KC0-56TM-VLBF-78BN","volume":"6","author":"M Sheran","year":"2005","unstructured":"Sheran M (2005) The nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in the treatment of HIV. HIV Clin Trials 6(3):158\u2013168","journal-title":"HIV Clin Trials"},{"key":"325_CR74","first-page":"86","volume":"12","author":"R Nazziwa","year":"2012","unstructured":"Nazziwa R, Sekadde M, Kanyike F, Wobudeya E, Nabukeera-Barungi N (2012) Efavirenz poisoning in a 12 year old HIV negative African boy. Pan Afr Med J 12:86. 12:86, Epub 2012 Jul 26","journal-title":"Pan Afr Med J"},{"issue":"2","key":"325_CR75","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1086\/321828","volume":"33","author":"J Blanch","year":"2001","unstructured":"Blanch J, Corbella B, Garc\u00eda F, Parellada E, Gatell JM (2001) Manic syndrome associated with efavirenz overdose. Clin Infect Dis 33(2):270\u2013271","journal-title":"Clin Infect Dis"},{"issue":"1","key":"325_CR76","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1179\/joc.2007.19.1.110","volume":"19","author":"MB Pasticci","year":"2007","unstructured":"Pasticci MB, Bonora S, DICandilo F, Lapalorcia LM, Palladino N, Baldelli F (2007) Transitory severe CNS adverse effects after accidental efavirenz overdose during post-exposure HIV prophylaxis. J Chemother 19(1):110","journal-title":"J Chemother"},{"issue":"16","key":"325_CR77","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.2165\/0003495-200868160-00007","volume":"68","author":"ED Deeks","year":"2008","unstructured":"Deeks ED, Keating GM (2008) Etravirine. Drugs 68(16):2357\u20132372","journal-title":"Drugs"},{"issue":"6","key":"325_CR78","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2165\/00003495-200060060-00013","volume":"60","author":"LJ Scott","year":"2000","unstructured":"Scott LJ, Perry CM (2000) Delavirdine: a review of its use in HIV infection. Drugs 60(6):1411\u20131444","journal-title":"Drugs"},{"issue":"9102","key":"325_CR79","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0140-6736(97)04161-5","volume":"351","author":"DW Cameron","year":"1998","unstructured":"Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C et al (1998) Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease, The Advanced HIV Disease Ritonavir Study Group. Lancet 351(9102):543\u2013549","journal-title":"Lancet"},{"issue":"7","key":"325_CR80","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","volume":"12","author":"A Carr","year":"1998","unstructured":"Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ et al (1998) A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12(7):F51\u2013F58","journal-title":"AIDS"},{"issue":"Suppl 2","key":"325_CR81","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1097\/QAI.0b013e318186519c","volume":"49","author":"DP Kotler","year":"2008","unstructured":"Kotler DP (2008) HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients. J Acquir Immune Defic Syndr 49(Suppl 2):S79\u2013S85","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"325_CR82","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1097\/QAD.0b013e32832ba904","volume":"23","author":"TL Stanley","year":"2009","unstructured":"Stanley TL, Joy T, Hadigan CM, Liebau JG, Makimura H, Chen CY et al (2009) Effects of switching from lopinavir\/ritonavir to atazanavir\/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients. AIDS 23(11):1349\u20131357","journal-title":"AIDS"},{"issue":"17","key":"325_CR83","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa062744","volume":"356","author":"DAD Study Group, Friis-M\u00f8ller N, Reiss P, Sabin CA, Weber R, Monforte AD, El-Sadr W, Thiebaut R, DeWit S, Kirk O, Fontas E, Law S, Phillips A, Lundgren JD","year":"2007","unstructured":"DAD Study Group, Friis-M\u00f8ller N, Reiss P, Sabin CA, Weber R, Monforte AD, El-Sadr W, Thiebaut R, DeWit S, Kirk O, Fontas E, Law S, Phillips A, Lundgren JD (2007) Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 356(17):1723\u20131735","journal-title":"N Engl J Med"},{"issue":"8","key":"325_CR84","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1056\/NEJMoa022048","volume":"348","author":"SA Bozzette","year":"2003","unstructured":"Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA (2003) Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 348(8):702\u2013710","journal-title":"N Engl J Med"},{"issue":"10","key":"325_CR85","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1001\/archinte.165.10.1179","volume":"165","author":"TT Brown","year":"2005","unstructured":"Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA et al (2005) Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 165(10):1179\u20131184","journal-title":"Arch Intern Med"},{"issue":"6","key":"325_CR86","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/COH.0b013e3283139134","volume":"3","author":"PW Hruz","year":"2008","unstructured":"Hruz PW (2008) HIV protease inhibitors and insulin resistance: lessons from in-vitro, rodent and healthy human volunteer models. Curr Opin HIV AIDS 3(6):660\u2013665","journal-title":"Curr Opin HIV AIDS"},{"issue":"47","key":"325_CR87","doi-asserted-by":"crossref","first-page":"36395","DOI":"10.1074\/jbc.M110.176321","volume":"285","author":"AK Vyas","year":"2010","unstructured":"Vyas AK, Koster JC, Tzekov A, Hruz PW (2010) Effects of the HIV protease inhibitor ritonavir on GLUT4 knock-out mice. J Biol Chem 285(47):36395\u201336400, Epub 2010 Sep 23","journal-title":"J Biol Chem"},{"issue":"9170","key":"325_CR88","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","volume":"353","author":"A Carr","year":"1999","unstructured":"Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA (1999) Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353(9170):2093\u20132099","journal-title":"Lancet"},{"issue":"18","key":"325_CR89","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJM199804303381808","volume":"338","author":"C Flexner","year":"1998","unstructured":"Flexner C (1998) HIV-protease inhibitors. N Engl J Med 338(18):1281\u20131292","journal-title":"N Engl J Med"},{"issue":"1","key":"325_CR90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1310\/hct0901-1","volume":"9","author":"RL Murphy","year":"2008","unstructured":"Murphy RL, da Silva BA, Hicks CB, Eron JJ, Gulick RM, Thompson MA et al (2008) Seven-year efficacy of a lopinavir\/ritonavir-based regimen in antiretroviral-na\u00efve HIV-1-infected patients. HIV Clin Trials 9(1):1\u201310","journal-title":"HIV Clin Trials"},{"issue":"6","key":"325_CR91","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/QAD.0b013e3282f4a0dd","volume":"22","author":"DM Roberts","year":"2008","unstructured":"Roberts DM, Ray JE, Buckley NA (2008) Mild clinical toxicity and dose-dependent pharmacokinetics following acute lopinavir\/ritonavir poisoning in a HIV-positive patient. AIDS 22(6):792\u2013793","journal-title":"AIDS"},{"issue":"4","key":"325_CR92","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00003495-200969040-00007","volume":"69","author":"K McKeage","year":"2009","unstructured":"McKeage K, Perry CM, Keam SJ (2009) Darunavir: a review of its use in the management of HIV infection in adults. Drugs 69(4):477\u2013503","journal-title":"Drugs"},{"issue":"13","key":"325_CR93","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1097\/QAD.0b013e32832d7350","volume":"23","author":"AM Mills","year":"2009","unstructured":"Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard PM et al (2009) Once-daily darunavir\/ritonavir vs. lopinavir\/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 23(13):1679\u20131688","journal-title":"AIDS"},{"issue":"9568","key":"325_CR94","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(07)60497-8","volume":"369","author":"B Clotet","year":"2007","unstructured":"Clotet B, Bellos N, Molina JM, POWER 1 and 2 study groups et al (2007) Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 369(9568):1169\u20131178","journal-title":"Lancet"},{"issue":"3","key":"325_CR95","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/FTD.0b013e3182511efe","volume":"34","author":"NY Rakhmanina","year":"2012","unstructured":"Rakhmanina NY, Neely MN, Capparelli EV (2012) High dose of darunavir in treatment-experienced HIV-infected adolescent results in virologic suppression and improved CD4 cell count. Ther Drug Monit 34(3):237\u2013241","journal-title":"Ther Drug Monit"},{"issue":"6","key":"325_CR96","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2165\/00003495-199958060-00011","volume":"58","author":"GL Plosker","year":"1999","unstructured":"Plosker GL, Noble S (1999) Indinavir: a review of its use in the management of HIV infection. Drugs 58(6):1165\u20131203","journal-title":"Drugs"},{"issue":"2","key":"325_CR97","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11255-010-9751-6","volume":"43","author":"J Huynh","year":"2011","unstructured":"Huynh J, Hever A, Tom T, Sim JJ (2011) Indinavir-induced nephrolithiasis three and one-half years after cessation of indinavir therapy. Int Urol Nephrol 43(2):571\u2013573, Epub 2010May 11","journal-title":"Int Urol Nephrol"},{"key":"325_CR98","unstructured":"Crixivan [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc; 2004"},{"issue":"2","key":"325_CR99","doi-asserted-by":"crossref","first-page":"119","DOI":"10.7326\/0003-4819-127-2-199707150-00004","volume":"127","author":"JB Kopp","year":"1997","unstructured":"Kopp JB, Miller KD, Mican JA, Feuerstein IM, Vaughan E, Baker C et al (1997) Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 127(2):119\u2013125","journal-title":"Ann Intern Med"},{"issue":"6","key":"325_CR100","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/pds.868","volume":"12","author":"HP Lehman","year":"2003","unstructured":"Lehman HP, Benson JO, Beninger PR, Anderson CA, Blumenthal SJ, Sharrar RG (2003) A five-year evaluation of reports of overdose with indinavir sulfate. Pharmacoepidemiol Drug Saf 12(6):449\u2013457","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"325_CR101","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2165\/00003495-200868100-00006","volume":"68","author":"JS Orman","year":"2008","unstructured":"Orman JS, Perry CM (2008) Tipranavir: a review of its use in the management of HIV infection. Drugs 68(10):1435","journal-title":"Drugs"},{"key":"325_CR102","unstructured":"Drugs @ FDA [webpage on the Internet]. FDA approved drug products. Silver Spring, MD: U.S. Food and Drug Administration. [updated 2012 Feb 17; cited 2012 Dec 1]. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021814s013,022292s006lbl.pdf"},{"issue":"7\u20138","key":"325_CR103","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1345\/aph.1G598","volume":"40","author":"BJ Dong","year":"2006","unstructured":"Dong BJ, Cocohoba JM (2006) Tipranavir: a protease inhibitor for HIV salvage therapy. Ann Pharmacother 40(7\u20138):1311\u20131321, Epub 2006Jun 20","journal-title":"Ann Pharmacother"},{"issue":"9","key":"325_CR104","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1086\/592302","volume":"47","author":"Justice AC, Zingmond DS, Gordon KS, Fultz SL, Goulet JL, King JT Jr, Bravata DM, Valdez H, Kraft M, Mattocks KM, Veterans Aging Cohort Study Project Team","year":"2008","unstructured":"Justice AC, Zingmond DS, Gordon KS, Fultz SL, Goulet JL, King JT Jr, Bravata DM, Valdez H, Kraft M, Mattocks KM, Veterans Aging Cohort Study Project Team (2008) Drug toxicity, HIV progression, or comorbidity of aging: does tipranavir use increase the risk of intracranial hemorrhage? Clin Infect Dis 47(9):1226\u20131230","journal-title":"Clin Infect Dis"},{"issue":"2","key":"325_CR105","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/jac\/dkm486","volume":"61","author":"J Graff","year":"2008","unstructured":"Graff J, von Hentig N, Kuczka K, Angioni C, Gute P, Klauke S et al (2008) Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo. J Antimicrob Chemother 61(2):394\u2013399, Epub 2007 Dec 21","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"325_CR106","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2165\/00003495-200969080-00009","volume":"69","author":"KF Croom","year":"2009","unstructured":"Croom KF, Dhillon S, Keam SJ (2009) Atazanavir: a review of its use in the management of HIV-1 infection. Drugs 69(8):1107\u20131140","journal-title":"Drugs"},{"issue":"5","key":"325_CR107","doi-asserted-by":"crossref","first-page":"259264","DOI":"10.1089\/apc.2011.0092","volume":"26","author":"C McDonald","year":"2012","unstructured":"McDonald C, Uy J, Hu W, Wirtz V, Juethner S, Butcher D et al (2012) Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir\/ritonavir through 96 weeks in the CASTLE study. AIDS Patient Care STDS 26(5):259264, Epub 2012Mar 9","journal-title":"AIDS Patient Care STDS"},{"issue":"3","key":"325_CR108","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2165\/00003495-200059030-00014","volume":"59","author":"A Bardsley-Elliot","year":"2000","unstructured":"Bardsley-Elliot A, Plosker GL (2000) Nelfinavir: an update on its use in HIV infection. Drugs 59(3):581\u2013620","journal-title":"Drugs"},{"issue":"5","key":"325_CR109","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/00003495-200565050-00005","volume":"65","author":"C Arvieux","year":"2005","unstructured":"Arvieux C, Tribut O (2005) Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile. Drugs 65(5):633\u2013659","journal-title":"Drugs"},{"issue":"7","key":"325_CR110","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1086\/319284","volume":"183","author":"KA Nagashima","year":"2001","unstructured":"Nagashima KA, Thompson DA, Rosenfield SI, Maddon PJ, Dragic T, Olson WC (2001) Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potentially synergistic in blocking virus-cell and cell-cell fusion. J Infect Dis 183(7):1121\u20131125, Epub 2001 Mar 8","journal-title":"J Infect Dis"},{"issue":"24","key":"325_CR111","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.2165\/00003495-200363240-00005","volume":"63","author":"TM Dando","year":"2003","unstructured":"Dando TM, Perry CM (2003) Enfuvirtide. Drugs 63(24):2755\u20132766","journal-title":"Drugs"},{"issue":"2","key":"325_CR112","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1086\/589289","volume":"47","author":"RD MacArthur","year":"2008","unstructured":"MacArthur RD, Novak RM (2008) Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis 47(2):236\u2013241","journal-title":"Clin Infect Dis"},{"issue":"5","key":"325_CR113","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/QAI.0b013e3181ee3d82","volume":"55","author":"WD Hardy","year":"2010","unstructured":"Hardy WD, Gulick RM, Mayer H, F\u00e4tkenheuer G, Nelson M, Heera J et al (2010) Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCRt-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. J Acquir Immune Defic Syndr 55(5):558\u2013564","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"325_CR114","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1586\/14787210.5.1.67","volume":"5","author":"L Palmisano","year":"2007","unstructured":"Palmisano L (2007) Role of integrase inhibitors in the treatment of HIV disease. Expert Rev Anti Infect Ther 5(1):67\u201375","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"7","key":"325_CR115","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1086\/597290","volume":"48","author":"C Hicks","year":"2009","unstructured":"Hicks C, Gulick RM (2009) Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis 48(7):931\u2013939","journal-title":"Clin Infect Dis"},{"key":"325_CR116","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1749-6632.2011.05972.x","volume":"1222","author":"BY Nguyen","year":"2011","unstructured":"Nguyen BY, Isaacs RD, Teppler H, Leavitt RY, Sklar P, Iwamoto M, Wenning LA et al (2011) Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium. Ann N Y Acad Sci 1222:83\u201389","journal-title":"Ann N Y Acad Sci"}],"container-title":["Journal of Medical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-013-0325-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13181-013-0325-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-013-0325-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-013-0325-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T12:12:12Z","timestamp":1659096732000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13181-013-0325-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,21]]},"references-count":117,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["325"],"URL":"https:\/\/doi.org\/10.1007\/s13181-013-0325-8","relation":{},"ISSN":["1556-9039","1937-6995"],"issn-type":[{"value":"1556-9039","type":"print"},{"value":"1937-6995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,21]]},"assertion":[{"value":"21 August 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}